Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival Models.
暂无分享,去创建一个
Iain Bennett | Noman Paracha | Keith Abrams | Joshua Ray | K. Abrams | J. Ray | N. Paracha | I. Bennett
[1] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[2] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] Sung-Bae Kim,et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.
[4] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[5] Mark Sculpher,et al. REPORT BY THE DECISION SUPPORT UNIT , 2010 .
[6] J. Robins,et al. Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .
[7] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[8] Keith R Abrams,et al. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study , 2018, Statistical methods in medical research.
[9] P C Lambert,et al. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method , 2017, Statistical methods in medical research.
[10] Nicholas R Latimer,et al. Treatment switching in oncology trials and the acceptability of adjustment methods , 2015, Expert review of pharmacoeconomics & outcomes research.
[11] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[12] Sandeep K. Gupta,et al. Intention-to-treat concept: A review , 2011, Perspectives in clinical research.
[13] Keith R Abrams,et al. Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] K. Abrams,et al. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study , 2011, BMC medical research methodology.
[15] R. Herbst,et al. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. , 2017 .
[16] Gianluca Baio,et al. Probabilistic sensitivity analysis in health economics , 2015, Statistical methods in medical research.
[17] Ian R. White,et al. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.
[18] J. Robins,et al. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.